4CPS-144 Effectiveness and safety of induction therapy with vedolizumab in patients with intestinal inflammatory disease

BACKGROUND: Vedolizumab is a therapeutic alternative indicated in patients with moderate-severe inflammatory bowel disease (IBD) (ulcerative colitis (UC) and Crohn’s Disease (CD)) with loss of response or intolerance to first-line treatment. PURPOSE: To evaluate the effectiveness and safety of induc...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Eur J Hosp Pharm
Hlavní autoři: Muñoz, C Gallego, Candel, M Gil, Navalón, C Iniesta, Requejo, C Caballero, Candela, M Onteniente, Valverde, I Salar
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Group 2018
Témata:
Section 4: Clinical pharmacy services
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535490/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.235
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky